QualityStocksNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)
Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced its completion of the manufacturing scale-up of REQORSA(TM) immunogene therapy. Subject to satisfactory completion of final testing currently underway, the clinical-grade production is intended to supply Genprex’s upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer. The company recently announced the successful manufacturing technology transfer to commercial contract development and manufacturing organizations (“CDMOs”) as well as the successful engineering run of REQORSA, which passed all testing specifications. “The scaled-up production of clinical-grade REQORSA is yet another significant manufacturing milestone…